A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumours

Official Title

A Phase II, Open-Label, Multicentre, Platform Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumours

Summary:

This study will evaluate the efficacy and safety of multiple biomarker-driven treatments in patients with persistent or recurrent rare epithelial ovarian, fallopian tube, or primary peritoneal tumours. Enrollment will take place in two phases: a preliminary phase followed by a potential expansion phase.

Trial Description

Primary Outcome:

  • Confirmed Objective Response Rate (ORR)
Secondary Outcome:
  • Duration of Response (DOR)
  • Disease Contral Rate (DCR)
  • Progression Free Survival (PFS)
  • Overall Survival (OS)
  • Confirmed ORR as Determined by IRC (Independent Review Committee)
  • DOR as Determined by IRC
  • DCR as Determined by IRC
  • PFS as Determined by IRC
  • Percentage of Participants With Adverse Events
  • Percentage of Participants With ADA-Positive and ADA-Negative to Atezolizumab
  • Number of Participants With ADA-Positive and ADA-Negative to Atezolizumab

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society